Tuberculosis Drug Discovery and Development 2019

• Autore: Riccardi Giovanna
• Pubblicazione: Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020
• Descrizione fisica: 1 online resource (296 p.)
• Soggetto topico: Biology, life sciences; Research & information: general
• Soggetto non controllato: anti-TB drug pipeline; anti-virulence compounds; antibiotic; antimicrobial drug resistance (AMR); antimycobacterial; antituberculosis agents; artificial pneumothorax; BCG; bedaquiline; biomarkers; Carlo Forlanini; caseum; cell envelope; clinical studies; clinical trial; CTVD; delpazolid; discovery; DNA gyrase; dormancy; DprE1 inhibitor; drug combination; drug development; drug discovery; drug resistance; drug-drug interactions; EDCTP; electron transport chain; energy metabolism; genomics; granulomas; host-directed therapy; IAVI; in vitro; in vivo; isoniazid; lead generation; lipidomics; macozinone; mechanism of action; mechanisms of resistance; metabolomics; MID3; mode of action; multi-drug resistance; mutations; mycobacteria; mycobacterium; Mycobacterium tuberculosis; n/a; oxidative phosphorylation; pharmacodynamics; pharmacokinetics; phenotypic screening; PknB; PknG; post-treatment sequelae; privileged targets; promiscuous targets; proteomics; pulmonary rehabilitation; Q203; rifampin; structure-based drug design; surgery; target; target identification; target-based drug design; target-based screening; TB; TBVI; toxicity; transcriptomics; tuberculosis; tuberculosis treatment; tuberculosis vaccines
• Persona (resp. second.): SalaClaudia; RiccardiGiovanna
• Sommario/riassunto: Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue.
• Titolo autorizzato: Tuberculosis Drug Discovery and Development 2019
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910557627203321
• Lo trovi qui: Univ. Federico II